TABLE 4.
Multivariate analysis of the overall survival of the surgery group divided into 6‐month periods of chemotherapy.
| Hazard ratio (95% CI) | p‐value | |
|---|---|---|
| Sex | ||
| Male | 1.58 (1.08, 2.33) | .020 |
| Female | 1 | |
| Age | ||
| <65 years | 1.30 (0.87, 1.95) | .202 |
| ≥65 years | 1 | |
| ECOG PS | ||
| 0 | 1.05 (0.61, 1.82) | .855 |
| 1 or 2 | 1 | |
| Extent of disease | ||
| Locally advanced | 0.82 (0.45, 1.51) | .523 |
| Metastatic | 1 | |
| Tumor location | ||
| Head | 0.85 (0.57, 1.26) | .425 |
| Body or tail | 1 | |
| Tumor diameter prior to chemotherapy | 1.00 (0.98, 1.01) | .964 |
| Regional lymph node metastasis prior to chemotherapy | ||
| Yes | 0.90 (0.58, 1.40) | .649 |
| No | 1 | |
| Arterial invasion prior to chemotherapy | ||
| Yes | 1.05 (0.58, 1.91) | .865 |
| No | 1 | |
| Portal vein invasion prior to chemotherapy | ||
| Yes | 1.21 (0.79, 1.86) | .373 |
| No | 1 | |
| Chemotherapy | ||
| FOLFIRINOX | 0.38 (0.22, 0.65) | <.001 |
| GnP | 1 | |
| RECIST version 1.1 | ||
| CR/PR | 0.56 (0.36, 0.88) | .013 |
| SD | 1 | |
| Chemotherapy duration | ||
| <6 months | 0.75 (0.31, 1.79) | .518 |
| ≥6 months | 1 | |
| Radiotherapy | ||
| None | 1.25 (0.73, 2.17) | .417 |
| Performed | 1 | |
| CEA prior to chemotherapy | ||
| Normal | 1.12 (0.73, 1.72) | .604 |
| Abnormal | 1 | |
| CA 19‐9 prior to chemotherapy | ||
| Normal | 0.89 (0.48, 1.64) | .701 |
| Abnormal | 1 |
Abbreviations: CA 19‐9, serum carbohydrate antigen 19‐9; CEA, serum carcinoembryonic antigen; CI, confidence interval; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFIRINOX, 5‐fluorouracil, leucovorin, irinotecan, and oxaliplatin; GnP, gemcitabine plus nab‐paclitaxel; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.